Dimerix Ltd
DXB
Company Profile
Business description
Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.
Contact
425 Smith Street
FitzroyVIC3065
AUST: +61 1300813321
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
9
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,820.30 | 6.40 | -0.07% |
| CAC 40 | 7,869.66 | 32.59 | -0.41% |
| DAX 40 | 24,319.99 | 136.82 | -0.56% |
| Dow JONES (US) | 44,650.64 | 192.34 | 0.43% |
| FTSE 100 | 8,980.36 | 4.70 | 0.05% |
| HKSE | 24,203.62 | 175.25 | 0.73% |
| NASDAQ | 20,630.66 | 19.33 | 0.09% |
| Nikkei 225 | 39,569.68 | 76.68 | -0.19% |
| NZX 50 Index | 12,686.68 | 73.52 | -0.58% |
| S&P 500 | 6,280.46 | 17.20 | 0.27% |
| S&P/ASX 200 | 8,580.10 | 9.10 | -0.11% |
| SSE Composite Index | 3,510.18 | 0.50 | 0.01% |